美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Prevail Therapeutics

23.00

0.0000

成交量：- -

成交額：- -

市值：1.58億

市盈率：-9.96

高：23.00

開：23.00

低：23.00

收：23.00

52周最高：23.35

52周最低：9.02

股本：687.33萬

流通股本：202.45萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-2.3102

每股收益(LYR):-2.2175

淨資產收益率：-52.34%

總資產收益率：-29.11%

市淨率：1.40

市盈率(LYR):-10.37

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Prevail Therapeutics

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.prevailtherapeutics.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Prevail Therapeutics Inc.於2017年7月6日根據特拉華州法律註冊成立。他們是一家利用人類遺傳學突破的基因治療公司，旨在為破壞性疾病患者開發和商業化基於疾病的AAV基因療法及神經退行性疾病。他們通過在遺傳定義的患者群體中研究他們的基因療法，將精確醫學方法應用於神經變性。他們的首要項目是用於治療帕金森病的PR001，其中包括GBA1突變，或PD-GBA，以及神經病理性戈謝病。他們致力於為一系列神經退行性疾病開發廣泛的基因療法，包括用於治療伴有GRN突變的額顳葉痴獃的PR006和用於治療突觸核蛋白病的PR004。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/PRVL/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PRVL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PRVL\",,,,,undefined,":{"symbol":"PRVL","market":"US","secType":"STK","nameCN":"Prevail Therapeutics","latestPrice":23,"timestamp":1611262800000,"preClose":23,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":2024501,"shares":6873344,"eps":-2.310192,"marketStatus":"停牌","change":0,"latestTime":"02-23 11:38:02 EST","open":23,"high":23,"low":23,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.310192,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1771880400000},"marketStatusCode":2,"adr":0,"listingDate":1561003200000,"exchange":"NASDAQ","adjPreClose":23,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PRVL\",,,,,undefined,":{"symbol":"PRVL","floatShares":2024501,"roa":"-29.11%","roe":"-52.34%","lyrEps":-2.217515,"shares":6873344,"dividePrice":0,"high":23,"amplitude":0,"preClose":23,"low":23,"week52Low":9.02,"pbRate":"1.40","week52High":23.35,"institutionHeld":0,"latestPrice":23,"eps":-2.310192,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.310192,"open":23,"prevYearClose":23.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PRVL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-01-25","symbol":"PRVL","reason":null,"defaultRemindTime":1611585000000,"announcedDate":"2021-01-14","type":"delisting","dateTimestamp":1611550800000},{"market":"US","date":"2020-11-13","symbol":"PRVL","fiscalQuarterEnding":"2020/09","expectedEps":-0.64,"name":null,"time":"","type":"earning","dateTimestamp":1605243600000,"reportTimeType":"","actualEps":-0.55},{"date":"2020-08-11","symbol":"PRVL","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2020/06","expectedEps":-0.59,"defaultRemindTime":1597132800000,"name":null,"time":"盤前","dateTimestamp":1597118400000,"actualEps":null},{"market":"US","date":"2020-05-14","symbol":"PRVL","fiscalQuarterEnding":"2020/03","expectedEps":-0.51,"name":null,"time":"盤前","type":"earning","dateTimestamp":1589428800000,"reportTimeType":"pre","actualEps":-0.56},{"market":"US","date":"2020-03-26","symbol":"PRVL","fiscalQuarterEnding":"2019/12","expectedEps":-0.64,"name":null,"time":"","type":"earning","dateTimestamp":1585195200000,"reportTimeType":"","actualEps":-0.53}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PRVL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PRVL\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PRVL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PRVL","date":"2021-01-22","current":-9.955882,"percent":0.521411,"low":-177.180696,"twenty":-127.865727,"median":-10.253791,"eighty":-5.510555,"high":-4.050302,"avg":-63.91702,"sd":61.834439,"marketCap":787704759},"quantilePoints":[],"updateTime":1771863064060},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.prevailtherapeutics.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Prevail Therapeutics Inc.於2017年7月6日根據特拉華州法律註冊成立。他們是一家利用人類遺傳學突破的基因治療公司，旨在為破壞性疾病患者開發和商業化基於疾病的AAV基因療法及神經退行性疾病。他們通過在遺傳定義的患者群體中研究他們的基因療法，將精確醫學方法應用於神經變性。 他們的首要項目是用於治療帕金森病的PR001，其中包括GBA1突變，或PD-GBA，以及神經病理性戈謝病。他們致力於為一系列神經退行性疾病開發廣泛的基因療法，包括用於治療伴有GRN突變的額顳葉痴獃的PR006和用於治療突觸核蛋白病的PR004。","exchange":"NASDAQ","name":"Prevail Therapeutics","nameEN":"Prevail Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PRVL\",market:\"US\",,,undefined,":null}}